摘要
目的:研究卵巢癌患者血清人附睾上皮分泌蛋白4(HE4)水平与卵巢癌病理类型的关系,探讨血清HE4检测在卵巢癌的应用价值。方法:比较卵巢癌组(210例)、卵巢良性疾病组(185例)和健康对照组(260例)血清HE4及癌抗原125(CA125)水平,并检测分析卵巢癌不同病理类型血清HE4水平。结果:卵巢癌组血清HE4水平(42.45 pmol/L)明显高于卵巢良性疾病组(17.35 pmol/L)和健康对照组(28.70 pmol/L),差异均有统计学意义(P<0.01);血清CA125水平在卵巢癌组(11.85 U/L)和卵巢良性疾病组(19.75 U/L)明显高于健康对照组(8.50 U/L),差异均有统计学意义(P<0.01)。卵巢癌组中混合性癌血清HE4水平(82.20 pmol/L)明显高于浆液性癌(53.20 pmol/L)和子宫内膜样癌(50.55 pmol/L),差异均有统计学意义(P<0.01,P<0.05)。结论:HE4是卵巢癌良好的生物标志物,HE4水平与卵巢癌病理类型有关。
Objective ：To investigate the relationship between serum humanepididymis protein 4（HE4） and dif- ferent pathological type of ovarian carcinoma and explore the application value of detection serum HE4 in ovarian cancer. Methods：Detecting and comparing serum HE4 and CA125 levels in 210 patients with ovarian carcinoma, 185 patients with benign ovarian disorders and 260 normal controls. Detecting and analyzing serum HE4 level in different pathological types of ovarian cancer. Results：The serum level of HE4 in patients with ovarian carcinoma （42.45 pmol/L）was significantly higher than those in patients with benign ovarian disorders（17. 35 pmoVL）and controls（28.70 pmoVL） （both P〈0. 01 ）. The serum level of CA125 in ovarian carcinoma（11.85 U/L）and benign ovarian disorders（19. 75 U/L）were significantly higher than that in the healthy controls （8.50 U/L）, and the differences had statistically significant （ both P 〈 0. 01 ）. Among the patients with ovarian carcinoma, the serum HE4 levels in patients with serous carcinoma （53. 20 pmol/L） and endometrium-like carcinoma （50.55 pmol/L） were significantly lower than those in patients with mixed carcinoma（82.2 pmol/L）（ P 〈 0.01, 〈 0.05）. Conclu- sions：Serum HE4 is an useful biomarker for ovarian carcinoma and the levels differ in pathological type of ovari- an carcinoma.
出处
《实用妇产科杂志》
CAS
CSCD
北大核心
2015年第4期267-270,共4页
Journal of Practical Obstetrics and Gynecology
